Related Experiment Videos
Simultaneous administration of live attenuated measles vaccine with DTP vaccine
Insights
Live attenuated measles vaccine can be given with diphtheria-tetanus toxoids or DTP vaccine. Immunogenicity was similar across groups, allowing flexible immunization schedules for measles and DTP vaccines.
Area of Science:
- Immunology
- Vaccinology
- Pediatrics
Background:
- Measles remains a significant public health concern globally.
- Effective vaccination strategies are crucial for measles control.
- Simultaneous administration of multiple vaccines requires assessment of immunogenicity.
Purpose of the Study:
- To evaluate the immunogenicity of live attenuated measles vaccine when co-administered with diphtheria-tetanus toxoids or diphtheria, tetanus toxoids, and pertussis (DTP) vaccine.
- To determine if simultaneous vaccination compromises the immune response to either measles or DTP components.
Main Methods:
- A study involving Cameroonian children aged 12 to 39 months.
- Participants received measles vaccine alone or combined with diphtheria-tetanus toxoids or DTP vaccine.
- Serological assessments (hemagglutination inhibition antibodies for measles) were performed before and after vaccination.
Main Results:
- Children initially seronegative for measles showed similar seroconversion rates and post-vaccination titers regardless of co-administration.
- The pertussis component of the DTP vaccine was confirmed as potent through laboratory testing and recipient serologic response.
- No compromise in the immunogenicity of either vaccine when administered simultaneously was observed.
Conclusions:
- Live attenuated measles vaccine and DTP vaccine can be safely co-administered.
- Simultaneous vaccination does not impair the immunogenicity of measles or DTP vaccines.
- Findings support increased flexibility in pediatric immunization schedules, potentially improving coverage rates.
Abstract:
Live attenuated measles vaccine was administered to Cameroonian children 12 to 39 months of age alone or with either diphtheria-tetanus toxoids or diphtheria and tetanus toxoids and pertussis (DTP) vaccine. Among children who were initially seronegative for measles hemagglutination inhibition antibodies, seroconversion rates and postvaccination geometric mean titers were similar in all groups. Pertussis antigen in the DTP vaccine was judged to be potent by laboratory potency testing and serologic response in recipients of the vaccine. Thus, the two vaccines may be administered simultaneously without compromising their immunogenicity. These results allow greater flexibility in planning individual or mass immunization schedules.